(Q33308317)

25 July 2017

title

Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial (English)

1 reference

25 July 2017

main subject

phase I clinical trial

0 references

author name string

John Hayslip

1

1 reference

25 July 2017

Uzair Chaudhary

2

1 reference

25 July 2017

Mark Green

3

1 reference

25 July 2017

Mario Meyer

4

1 reference

25 July 2017

Steven Dunder

5

1 reference

25 July 2017

Carol Sherman

6

1 reference

25 July 2017

Shanta Salzer

7

1 reference

25 July 2017

Andrew Kraft

8

1 reference

25 July 2017

Alberto J Montero

9

1 reference

25 July 2017

language of work or name

English

0 references

publication date

3 December 2007

1 reference

25 July 2017

1 reference

25 July 2017

volume

7

1 reference

25 July 2017

page(s)

221

1 reference

The ubiquitin-proteasome system

25 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

The ubiquitin system: from basic mechanisms to the patient bed.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

Role of cyclooxygenases in angiogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

How proteolysis drives the cell cycle

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

p53 is required for radiation-induced apoptosis in mouse thymocytes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

Aspirin use and risk of fatal cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

Expression of cyclooxygenase-1 and -2 in human colorectal cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-221

Nonsteroidal antiinflammatory drugs and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-221

Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-221

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-221

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-221

A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-7-221

The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2234426

Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor

31 October 2018

1 reference

12 December 2020

Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel

1 reference

12 December 2020

Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study

1 reference

12 December 2020

Aspirin use and the risk for colorectal cancer and adenoma in male health professionals

1 reference

12 December 2020

The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression

1 reference

12 December 2020

Aspirin and reduced risk of esophageal carcinoma

1 reference

12 December 2020

Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy

1 reference

12 December 2020

Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung Cancer

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-7-221

1 reference

Dimensions Publication ID

25 July 2017

0 references

1 reference

25 July 2017

1 reference